Observed, adjusted and mean applicability score difference using mixed effect model controlling for publication year, country and type of guideline developer nested within the review source, 2008–2013
| Factor | Observed mean applicability score | Adjusted mean applicability score (95% CI) | Mean applicability score difference | p Value |
|---|---|---|---|---|
| Guideline publication year | ||||
| 2008 | 47.0 | 47 (33.2 to 60.7) | 24.0 | 0.48 |
| 2009 | 47.7 | 45.8 (32.1 to 59.5) | 22.8 | 0.06 |
| 2010 | 47.7 | 49.5 (36.0 to 63.0) | 26.5 | 0.03* |
| 2011 | 31.1 | 41.3 (26.6 to 55.9) | 18.3 | 0.14 |
| 2012 | 41.9 | 51.3 (35.2 to 67.4) | 28.3 | 0.02* |
| 2013 | 16.3 | 23 (−3.1 to 49.1) | Reference | |
| Country | ||||
| International group | 35.9 | 35.7 (21.9 to 49.4) | −26.1 | <0.001* |
| Canada | 47.9 | 42.0 (26.7 to 57.3) | −19.8 | <0.001* |
| USA | 38.6 | 32.3 (18.2 to 46.4) | −29.5 | <0.001* |
| UK | 64.4 | 61.8 (46.3 to 77.3) | Reference | |
| Type of guideline developer | ||||
| Disease-specific foundation | 50.0 | 56.5 (42.7 to 70.3) | 16.2 | 0.01* |
| Non-profit healthcare system | 49.7 | 55.2 (38.5 to 71.9) | 14.9 | 0.04* |
| Government agency | 48.1 | 44.4 (31.4 to 57.4) | 4.1 | 0.4 |
| Academic organisation | 40.7 | 53.6 (34.1 to 73.1) | 13.3 | 0.14 |
| Professional organisation | 39.7 | 40.3 (28.7 to 51.9) | Reference | |
*All p values two-sided, significance level 0.05.